Import substitution of drugs in Russia

Import substitution in Russia

Main article: Import substitution in Russia

Pharmaceutical market of Russia

Main article: Pharmaceutical market of Russia

Chronicle

2023: The production of pharmaceutical substances opened in Saransk will allow to establish a full cycle of drug creation within the country

On March 30, 2023, a BiochemistPromomed plant for the production of active pharmaceutical substances (API), which is one of the largest in, was opened on the basis of JSC "JSC, which is part of the group of companies. to the country This was Zdrav.Expert announced on March 30, 2023 by representatives of Promomed. According to them, the production capacity is 340 tons per year for 150 types of substances. Investments in the project exceeded 3.7 billion. rubles

According to the Chairman of the Board of Directors of the Promomed Group of Companies Pyotr Beliy, the development of its own production of substances opens the way to obtain more innovative molecules, which will make it possible to become more independent of imports and establish a full cycle of creating medicines within the country. Read more here.

2022

FMBA began work with Rosatom and Rostec on the replacement of foreign drugs

On May 25, 2022, it became known that FMBA began work with Rosatom and Rostec on import substitution of medical devices.

This was FEDERATION COUNCIL announced at an expanded meeting of the Committee on Social Policy by the head of the Federal Medical and Biological Agency. Veronika Skvortsova Also, the work has been launched to replace foreign drugs. According to Skvortsova, Russia it is planned to create, among other things, analogues of some drugs for the treatment of orphan diseases. For example, the medication "," Zolgensma which is used for therapy. spinal muscular atrophy It is expected that the domestic drug will cost tens of times cheaper than^[1]

No one has canceled responsibility to the patient

At a recent meeting with the head of the Federal Customs Service Vladimir Bulavin, Prime Minister Mikhail Mishustin said that essential goods, which include medicines and medical devices, should receive priority when passing customs procedures. Can such a measure affect technological sovereignty in domestic pharmaceuticals?

Attempts to minimize the negative consequences of the sanctions imposed against Russia were made by the customs department back in mid-March 2022. It was then that the first steps were taken to transfer the FCS to an enhanced work schedule.

In April 2022, the head of the department, Vladimir Bulavin, said that the volume of imports from the EU countries and the United States remained at the level of last year. At the same time, according to Reuters, which referred to its own sources, transport, insurance and customs difficulties still arise when delivering medicines and medical devices.

In this situation, the issue of technological sovereignty of the pharmaceutical industry is acute. How realistic is it to develop and produce modern drugs without the support of foreign pharmaceutical giants?

Experts are confident that it is impossible to create a pharmaceutical industry isolated from the global economy. Lack of access to modern technologies and products will significantly limit the development of the industry. In addition, large-scale investments will be needed.

"Capital comes where there is potential for development and growth - the isolation of the economy itself will be a limitation," said Anton Zybin, CEO of Lancet.

But even if foreign companies completely suspend investment projects in our country, modern innovative drugs will be available to Russians.

believe in market mechanisms for supply and demand regulation. In this sense, the presence of foreign manufacturing companies seems to me to be an important factor in the development of any industry in the economy, and in pharmaceutical in particular. At the same time, I would not exaggerate the influence of investment projects of foreign companies, "says Anton Zybin

The expert also touched upon such a problem as the suspension by Western pharmaceutical companies of clinical trials of new drugs in Russia.

It is important to understand here that clinical trials are not only investments - these are the lives of patients who take part in clinical trials. "They should not only receive therapy, but also be under regular supervision. All clinical parameters of their state of health should be in plain sight. Today, it is simply impossible to guarantee the uninterrupted movement of analyzes for specialized laboratories. In this sense, it is very important to talk about responsibility to patients, "the expert especially notes.

2021: ROC concerned about import substitution of drug production in Russia

In January 2022, it became known about the concern of the Russian Orthodox Church (ROC) about the import substitution of drug production in Russia. The corresponding letter was sent by the Holy Synod of the Russian Orthodox Church (Moscow Patriarchate) to the director of the Health Department of the Government of the Russian Federation of Grief Kagramanyan.

This report says that a resident of the Belgorod region sent an appeal to His Holiness Patriarch of Moscow and All Russia Kirill, in which she expressed concern about the adoption by the government of the resolution "On Amending the Decree of the Government of the Russian Federation of November 30, 2015 No. 1289." This document changes the procedure for purchasing vital foreign drugs.

ROC is concerned about import substitution of drug production in Russia

According to the author of this appeal, the implementation of this decree will make it difficult to treat rare diseases using modern medical protocols, and will also make the necessary drugs inaccessible. The Russian Orthodox Church asked the government to pay attention to this appeal and assist in solving the indicated problem.

In December 2021, Prime Minister Mikhail Mishustin signed an order to include 22 more names in the list of vital drugs. Now there are 808 drugs on the list. It was supplemented by drugs for the treatment of spinal muscular atrophy (risdiplam), breast cancer (thalazoparib), cystic fibrosis (ivacaftor + lumacaftor), multiple sclerosis (cladribine, siponimod). Also new are drugs for the treatment of multiple myeloma (isatuximab, pomalidomide), chronic hepatitis B (bulevirtide), pulmonary tuberculosis (delamanid), hospital infections (polymyxin B) and HIV infections (bictegravir + tenofovir alafenamide + emtricitabine, doravirin + lamivudine +^[2]Russia

Notes